Listing of Pharmasimple on Euronext Growth

Michael Willems, CEO and Founder of Pharmasimple , opens the trading day in Paris.

Pharmasimple specializes in the online sale of parapharmaceuticals. The company has 120,000 references (770 brands) of cosmetics and dermo-cosmetics, medical accessories and dietary supplements.The company has over 300,000 customers and nearly 120,000 orders per year.France accounts for 90% of net sales.

IPO Valbiotis

Listing of Valbiotis on Euronext

Sébastien Peltier, CEO of Valbiotis, opens the trading day in Paris.

Valbiotis is a biopharmaceutical company specializing in the research and development of preventive and therapeutic products based on polymolecular complexes indicated at specific stages of progression of chronic metabolic pathologies such as type 2 diabetes, obesity, dyslipidemia or NASH (Non-Alcoholic Steatosis Hepatic).

IPO Balta

Balta’s first trading day on Euronext Brussels

Euronext today celebrated the listing of Balta, a European market leader in soft flooring, on its Brussels market (Compartment B). Balta enters the top ten of household goods and home construction companies listed on Euronext for market capitalisation. This transaction is the largest IPO on Euronext Brussels since 2014

IPO Balyo

Listing of Balyo on Euronext

Fabien Bardinet, CEO of Balyo, opens the trading day in Paris.

Balyo specializes in the design, manufacturing and marketing of robotic handling trolleys for all logistics applications. The group offers stackers, tractors, pallet trucks, etc. capable of perceiving their environment with ease, interacting with the surrounding elements and completing tasks autonomously.

IPO Prodways

Listing of Prodways on Euronext

Raphaël Gorgé, CEO & Chairman of Prodways, opens the trading day in Paris.

Prodways Group is one of the leading European companies specializing in 3D printing for aeronautics, space, medical, dental, automotive and other industries. It is about an additive manufacturing process of creating physical objects by superimposing different layers of materials. Net sales (before intra-group eliminations) break down by activity as follows:

  • design, assembly and sales of machines and associated equipment (50.6%): 3D printers, cleaning stations, UV ovens, liquid resins, polymer powders, etc.;
  • design and manufacturing of 3D plastic and metal printed parts (46.9%);
  • other (2.5%).

Net sales are distributed geographically as follows: France (42.1%), Europe (32.8%), North America (18.9%) and other (6.2%).

EnterNext TechShare

Gong to conclude EnterNext TechShare program 2016-2017

To conclude the second successful EnterNext TechShare program 2016 – 2017 the Dutch participants and partners sound the gong. TechShare is an educational program designed specifically for fast growing tech companies who want to know more about the process of an IPO. The participants have had educational sessions on the capital market in recent months.

IPO Inventiva

Listing of Inventiva on Euronext

Frédéric Cren, Chairman and CEO and Co-Founder of Inventiva, opens the trading day in Paris.

Inventiva specializes in the research and development of therapeutic products for the treatment of Parkinson's disease, cancer, autoimmune diseases and fibrosis.
At the end of 2015, the company has a portfolio of five products, including 3 in pre-clinical development phase and 2 in clinical development.

10th anniversary Ascencio

10th listing anniversary Ascencio

Ascencio was a guest at Euronext Brussels to celebrate the 10th listing anniversary of this Public Regulated Real Estate Company (public SIR). To mark the occasion, Marc Brisack, General Manager of Ascencio, rang the opening bell in the presence of partners and teams of specialist in commercial premises situated on urban peripheries.


IPO Osmozis

Listing of Osmozis on Alternext

Gérard Tremblay, CEO and Yves Boulot, Managing Director, close the trading day in Paris.

Osmozis specializes in the development and operation of mesh networks of interconnected wifi terminals designed to provide broadband internet access in tourist establishments (campsites and holiday villages). Net sales break down by activity as follows:

  • sales of wifi Internet access (99.4%);
  • connected services (0.6%): including rental of connected devices such as video surveillance cameras and sound alert systems.

France accounts for 99.3% of net sales.


IPO Lysogène

Listing of Lysogène on Euronext

Karen Aiach, Founder and Managing Director, Lysogène, opens the trading day in Paris.

Lysogene is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases.
The company now has 2 products in development phase for the treatment of Sanfilippo syndrom and gangliosidosis.